Article Figures & Data
Figures
- FIGURE 1.
Binding of 3/A12 mAb and DOTA-3/A12 mAb, with and without serum preincubation, to PSMA-positive C4-2 cells. Cells were treated with increasing concentrations (0.15–800 nM) of first-step anti-PSMA mAb followed by incubation with saturating amount of second-step phycoerythrin-labeled goat antimouse IgG followed by cytofluorometric analysis. MFI = mean fluorescence intensity.
- FIGURE 2.
Blood immunoreactivity of 3/A12, DOTA-3/A12, and copper-DOTA-3/A12 in SCID mice after intravenous injection of 25 μg of mAb. Serum levels are given as mean fluorescence intensity (MFI) measured by flow cytometry.
- FIGURE 3.
Small-animal PET imaging of mice bearing PSMA-positive C4-2 tumors (pos control, C4-2) and PSMA-negative DU 145 tumors (neg control, DU145) 24 and 48 h after injection of 64Cu-DOTA-3/A12 mAb. Blocking experiments were performed by injecting unlabeled 3/A12 mAb 3 h before injection of 64Cu-labeled mAb (blocking, 700 μg of 3/A12 mAb). Arrows indicate position of tumors.
- FIGURE 4.
Blocking of 64Cu-DOTA-3/A12 mAb uptake in C4-2 tumors with 250, 500, or 700 μg of nonradioactive 3/A12 mAb, given 3 h before radiotracer injection. %ID/cm3 from mice bearing DU 145 tumors (negative control) or C4-2 tumors (positive control) 3, 24, and 48 h after injection of 64Cu-DOTA-3/A12 are shown.
- FIGURE 5.
Biodistribution by γ-counting of 64Cu-DOTA-3/A12 in various organs of mice 48 h after injection.
Jump to section
Related Articles
Cited By...
- A Novel Fully Human Antibody targeting Extracellular Domain of PSMA Inhibits Tumor Growth in Prostate Cancer
- Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen
- Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
- Optimization of Labeling PSMAHBED with Ethanol-Postprocessed 68Ga and Its Quality Control Systems
- ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo
- In Vivo Evaluation of 11C-DASB for Quantitative SERT Imaging in Rats and Mice
- Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer
- Advances in Immuno-Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
- 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
- Targeting Prostate Cancer Cells In Vivo Using a Rapidly Internalizing Novel Human Single-Chain Antibody Fragment
- New Agents and Techniques for Imaging Prostate Cancer